CEO and Executive Committee
Bhooshi de Silva
Bhooshi de Silva serves as global head of corporate development, strategy and ventures for PPD. He joined the company in 2014 as senior vice president of corporate development and strategy, serving as a member of PPD’s executive leadership team with responsibilities in mergers and acquisitions and partnerships. In his current role, in addition to corporate development and strategy, de Silva leads the company’s enterprise data functions and manages venture partnerships. He collaborates with the senior leadership team on key strategic initiatives, leads PPD’s data and disruptive innovation priorities, plays a key role in driving the company’s evolution and growth, and is a member of PPD’s commercial leadership team. Since joining PPD, de Silva has led the organization in completing several strategic partnerships and acquisitions, and in strengthening and expanding the company’s capabilities in priority focus areas. He is also serves on the boards of several of PPD’s strategic investments, including PPD-SNBL and Science 37.
In joining PPD, de Silva brought 15 years of biopharmaceutical industry experience, including serving in several leadership positions. He started his career at Pfizer, where his roles included R&D portfolio management, U.S. commercial development, and U.S. customer strategy and negotiations. In 2009, de Silva was named vice president of business development evaluation and strategy, leading a team in the evaluation of licensing, acquisitions and corporate strategic initiatives for Pfizer. Later, he served as head of corporate development, corporate strategy and head of international at Optimer Pharmaceuticals. De Silva played an integral role in the commercialization strategy and Optimer’s sale to Cubist Pharmaceuticals in 2013. He has an impressive track record of achievement in corporate strategic initiatives and M&A transactions on both the buy and sell sides.
De Silva holds degrees in finance, economics and engineering from Stanford University, London School of Economics and Imperial College of Science, Technology and Medicine in London.